cilostazol has been researched along with alprostadil in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chijiwa, T; Igawa, T; Kato, S; Kawamura, K; Kimura, Y; Shimidzu, S; Shiragiku, T; Tani, T; Unemi, F | 1 |
| Aoki, M; Hayashi, SI; Higaki, J; Matsumoto, K; Matsushita, H; Moriguchi, A; Morishita, R; Nakamura, S; Nakamura, T; Ogihara, T; Yo, Y | 1 |
| Adachi, T; Kimura, Y; Marukawa, K; Matsumoto, Y; Okumura, H; Tani, T | 1 |
| Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H | 1 |
| Hashiguchi, M; Ohno, K; Saito, R | 1 |
| Higashi, T; Horiuchi, H; Ikeda, T; Kawato, M; Kita, T; Morimoto, T; Shirakawa, R; Tabuchi, A; Takahashi, K; Watanabe, H; Yamamoto, H; Yoshikawa, Y | 1 |
| Fan, L; Liu, J; Yang, L; Zhang, C; Zhou, J | 1 |
| Fukasawa, I; Inoue, O; Kanemaru, K; Kimura, Y; Kinouchi, H; Ohta, M; Ozaki, Y; Satoh, K; Yoda, S | 1 |
1 review(s) available for cilostazol and alprostadil
| Article | Year |
|---|---|
Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication.
Topics: Alprostadil; Cilostazol; Epoprostenol; Humans; Intermittent Claudication; Platelet Aggregation Inhibitors; Tetrazoles; Treatment Outcome; Walking | 2004 |
1 trial(s) available for cilostazol and alprostadil
| Article | Year |
|---|---|
Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation.
Topics: Adult; Alprostadil; Blood Platelets; Cell Adhesion Molecules; Cilostazol; Humans; Male; Microfilament Proteins; Middle Aged; Phosphodiesterase 3 Inhibitors; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles | 2008 |
8 other study(ies) available for cilostazol and alprostadil
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 6-Ketoprostaglandin F1 alpha; Adenosine Diphosphate; Alprostadil; Azoles; Cells, Cultured; Cilostazol; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Thromboxane B2 | 1990 |
Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alprostadil; Aorta; Cell Death; Cells, Cultured; Cilostazol; Culture Media, Serum-Free; Cyclic Nucleotide Phosphodiesterases, Type 3; Dinoprostone; Endothelium, Vascular; Epoprostenol; Glucose; Hepatocyte Growth Factor; Humans; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Prostaglandins; Tetrazoles | 1997 |
Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
Topics: Abciximab; Alprostadil; Antibodies, Monoclonal; Blood Platelets; Cells, Cultured; Cilostazol; Cyclic AMP; Drug Evaluation, Preclinical; Hemostatics; Humans; Immunoglobulin Fab Fragments; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tetrazoles; Thrombin; Tirofiban; Tyrosine | 1999 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent Claudication; Male; Nifedipine; Platelet Aggregation; Rats; Rats, Wistar; Skin; Spinal Cord; Tetrazoles; Ticlopidine; Time Factors; Walking | 2003 |
Loading solution prevents activation damage of human platelets before lyophilization.
Topics: Adenosine; Algorithms; Alprostadil; Arginine; Biomarkers; Blood Platelets; Blood Preservation; Cell Size; Cilostazol; Excipients; Freeze Drying; Hirudins; Humans; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Membrane Glycoproteins; Recombinant Proteins; Tetrazoles | 2011 |
Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring.
Topics: Aged; Alprostadil; Arachidonic Acid; Blood Platelets; Cilostazol; Drug Monitoring; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Sensitivity and Specificity; Tetrazoles | 2012 |